Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.
Trends Mol Med. 2013 Jun;19(6):355-67. doi: 10.1016/j.molmed.2013.03.005. Epub 2013 Apr 17.
The enzymatic activities of CD39 and CD73 play strategic roles in calibrating the duration, magnitude, and chemical nature of purinergic signals delivered to immune cells through the conversion of ADP/ATP to AMP and AMP to adenosine, respectively. This drives a shift from an ATP-driven proinflammatory environment to an anti-inflammatory milieu induced by adenosine. The CD39/CD73 pathway changes dynamically with the pathophysiological context in which it is embedded. It is becoming increasingly appreciated that altering this catabolic machinery can change the course or dictate the outcome of several pathophysiological events, such as AIDS, autoimmune diseases, infections, atherosclerosis, ischemia-reperfusion injury, and cancer, suggesting these ectoenzymes are novel therapeutic targets for managing a variety of disorders.
CD39 和 CD73 的酶活性在调节免疫细胞接收到的嘌呤能信号的持续时间、幅度和化学性质方面发挥着战略作用，分别通过将 ADP/ATP 转化为 AMP 和 AMP 转化为腺苷来实现。这促使从由 ATP 驱动的促炎环境转变为由腺苷诱导的抗炎环境。CD39/CD73 途径会随着其所处的病理生理环境而动态变化。人们越来越认识到，改变这种分解代谢机制可以改变艾滋病、自身免疫性疾病、感染、动脉粥样硬化、缺血再灌注损伤和癌症等几种病理生理事件的进程或决定其结果，这表明这些细胞外酶是管理多种疾病的新型治疗靶点。
